BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 16557194)

  • 1. Extranodal marginal zone B-cell lymphoma most probably of MALT type appearing in CNS as parasagittal extracerebral tumor.
    Marinković M; Slavik E; Janković S; Cemerikic V; Radulović D
    J Neurosurg Sci; 2006 Mar; 50(1):9-12. PubMed ID: 16557194
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Primary central nervous system mucosa-associated lymphoid tissue lymphoma: case report and literature review.
    Razaq W; Goel A; Amin A; Grossbard ML
    Clin Lymphoma Myeloma; 2009 Jun; 9(3):E5-9. PubMed ID: 19525185
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nonpolypoid intestinal mantle cell lymphoma resembling MALT lymphoma with successful response to rituximab.
    D'Antonio A; Boscaino A; Addesso M; Liguori G; Nappi O
    South Med J; 2008 Nov; 101(11):1168-9. PubMed ID: 19088534
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Gastric lyphoma - still a result of surgery?].
    Fischbach W
    Chirurg; 2006 Jun; 77(6):512, 514-7. PubMed ID: 16773350
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rituximab plus CHOP as an initial chemotherapy for patients with disseminated MALT lymphoma.
    Ennishi D; Yokoyama M; Mishima Y; Watanabe C; Terui Y; Takahashi S; Takeuchi K; Ikeda K; Tanimoto M; Hatake K
    Leuk Lymphoma; 2007 Nov; 48(11):2241-3. PubMed ID: 17990181
    [No Abstract]   [Full Text] [Related]  

  • 6. Combined therapy with rituximab plus cyclophosphamide/doxorubicin/vincristine/prednisone (CHOP) for Sjögren's syndrome-associated B-cell aggressive non-Hodgkin's lymphomas.
    Voulgarelis M; Giannouli S; Anagnostou D; Tzioufas AG
    Rheumatology (Oxford); 2004 Aug; 43(8):1050-3. PubMed ID: 15187246
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical manifestations of primary pulmonary extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue in Japanese population.
    Ogusa E; Tomita N; Ishii Y; Takasaki H; Hattori Y; Matsumoto C; Ishigatsubo Y
    Hematol Oncol; 2013 Mar; 31(1):18-21. PubMed ID: 22278757
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ongoing monoclonal B-cell proliferation is not common in gastric B-cell lymphoma after combined radiochemotherapy.
    Alpen B; Kuse R; Parwaresch R; Müller-Hermelink HK; Stolte M; Neubauer A
    J Clin Oncol; 2004 Aug; 22(15):3039-45. PubMed ID: 15284253
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rituximab-CHOP induced interstitial pneumonitis in patients with disseminated extranodal marginal zone B cell lymphoma.
    Kim KM; Kim HC; Jeon KN; Kim HG; Kang JH; Hahm JR; Lee GW
    Yonsei Med J; 2008 Feb; 49(1):155-8. PubMed ID: 18306483
    [TBL] [Abstract][Full Text] [Related]  

  • 10. First-line treatment for primary testicular diffuse large B-cell lymphoma with rituximab-CHOP, CNS prophylaxis, and contralateral testis irradiation: final results of an international phase II trial.
    Vitolo U; Chiappella A; Ferreri AJ; Martelli M; Baldi I; Balzarotti M; Bottelli C; Conconi A; Gomez H; Lopez-Guillermo A; Martinelli G; Merli F; Novero D; Orsucci L; Pavone V; Ricardi U; Storti S; Gospodarowicz MK; Cavalli F; Sarris AH; Zucca E
    J Clin Oncol; 2011 Jul; 29(20):2766-72. PubMed ID: 21646602
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [A case of primary mucosa-associated lymphoid tissue lymphoma of the bladder regressed after rituximab in combination with CHOP chemotherapy].
    Kakuta Y; Katoh T; Saitoh J; Yazawa K; Hosomi M; Itoh K
    Hinyokika Kiyo; 2006 Dec; 52(12):951-4. PubMed ID: 17252980
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Central nervous system (CNS) relapse in diffuse large B cell lymphoma (DLBCL): pre- and post-rituximab.
    Tai WM; Chung J; Tang PL; Koo YX; Hou X; Tay KW; Quek R; Tao M; Lim ST
    Ann Hematol; 2011 Jul; 90(7):809-18. PubMed ID: 21229246
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
    Coiffier B; Lepage E; Briere J; Herbrecht R; Tilly H; Bouabdallah R; Morel P; Van Den Neste E; Salles G; Gaulard P; Reyes F; Lederlin P; Gisselbrecht C
    N Engl J Med; 2002 Jan; 346(4):235-42. PubMed ID: 11807147
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Prognosis of primary non-Hodgkin's lymphoma of the breast].
    Guo HY; Zhao XM; Cao JN; Hu XC; Yin JL; Hong XN; Li J
    Zhonghua Zhong Liu Za Zhi; 2008 Mar; 30(3):200-2. PubMed ID: 18756936
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lack of benefit of central nervous system prophylaxis for diffuse large B-cell lymphoma in the rituximab era: findings from a large national database.
    Kumar A; Vanderplas A; LaCasce AS; Rodriguez MA; Crosby AL; Lepisto E; Czuczman MS; Nademanee A; Niland J; Gordon LI; Millenson M; Zelenetz AD; Friedberg JW; Abel GA
    Cancer; 2012 Jun; 118(11):2944-51. PubMed ID: 22006274
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Therapeutic management of central nervous system lymphomas in a single hematological institute].
    Iványi JL; Marton E; Plander M; Gyánó G; Czumbil L; Tóth C
    Orv Hetil; 2009 Oct; 150(42):1937-44. PubMed ID: 19812012
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activity of rituximab plus cyclophosphamide, doxorubicin/mitoxantrone, vincristine and prednisone in patients with relapsed MALT lymphoma.
    Raderer M; Wohrer S; Streubel B; Drach J; Jager U; Turetschek K; Troch M; Puspok A; Zielinski CC; Chott A
    Oncology; 2006; 70(6):411-7. PubMed ID: 17220639
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high-risk patients with diffuse large B-cell lymphoma.
    Abramson JS; Hellmann M; Barnes JA; Hammerman P; Toomey C; Takvorian T; Muzikansky A; Hochberg EP
    Cancer; 2010 Sep; 116(18):4283-90. PubMed ID: 20564149
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG).
    Lenz G; Dreyling M; Hoster E; Wörmann B; Dührsen U; Metzner B; Eimermacher H; Neubauer A; Wandt H; Steinhauer H; Martin S; Heidemann E; Aldaoud A; Parwaresch R; Hasford J; Unterhalt M; Hiddemann W
    J Clin Oncol; 2005 Mar; 23(9):1984-92. PubMed ID: 15668467
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Successful treatment of relapse of an intravascular B-cell lymphoma with rituximab-CHOP polychemotherapy.
    Takács I; Eros N; Bene I; Bozsó F; Tordai L; Károlyi Z; Radványi G; Matolcsy A
    Ann Hematol; 2004 Sep; 83(9):608-10. PubMed ID: 15205915
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.